News

Oculus Innovative Sciences reported total revenue of $1.8m in the first quarter of FY2010, an increase of 52% over $1.2m in the first quarter of fiscal 2009. Product

Amgen has reported that Vectibix (panitumumab), administered in combination with Folfox (an oxaliplatin-based chemotherapy), prolonged progression-free survival (PFS), as compared to Folfox alone in the treatment of KRAS

Bellicum has initiated dosing of the first patient in a phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate

Emergent BioSolutions has executed multiple real estate transactions that will expand the company’s manufacturing and development infrastructure. The company expects that these transactions would broaden its manufacturing options.

Curis and Debiopharm have entered into an agreement for Curis’ Heat Shock Protein (Hsp90) technology, including CUDC-305, the company’s lead Hsp90 inhibitor candidate. Under the terms of the

Omnio Healer has entered into a partnership agreement with Eden Biodesign. Under the agreement, Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer’s

Alzheimer’s Drug Discovery Foundation (ADDF) has announced that the new therapeutics, developed by PharmatrophiX, has entered into a significant milestone in its development. ADDF also announced that PharmatrophiX

ViroPharma has initiated dosing in the phase 1 clinical trial for NTCD (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI). The phase

Watson has received a request for additional information from the Federal Trade Commission (FTC) in connection with Watson’s pending acquisition of Arrow Group. The information request was issued